SK Capital Partners, a New York-based private investment firm focused on life sciences, specialty materials, and ingredients, has reached a definitive agreement through an affiliate to invest in Swixx BioPharma AG as the company looks to accelerate its next phase of growth and global expansion. The transaction values Swixx at more than €1.5 billion.
Swixx is described as a global provider of “rest of world” pharmaceutical commercialization services, focused on bringing innovative medicines to underserved and hard-to-reach markets. The company supports biopharmaceutical partners by helping commercialize and distribute therapies in regions that can be complex for direct market entry.
As part of the transaction, Swixx co-founders Stuart Swanson and Petr Němec, along with CEO Jean-Michel Lespinasse and CFO Petr Pipal, will retain significant ownership stakes. Existing institutional investors HBM Healthcare Investments and Mérieux Equity Partners will also remain shareholders in Swixx following the investment.
Support: The parties also detailed the advisory teams supporting the transaction. Rothschild & Co. is serving as sole financial advisor to SK Capital, with Bär & Karrer and Kirkland & Ellis as legal counsel. KPMG LLP provided advisory on financial, tax, compliance, and IT due diligence, while ClearView Healthcare Partners advised on commercial due diligence. Ares Credit funds provided committed debt financing in support of the transaction. For Swixx and its shareholders, Jefferies acted as lead financial advisor, Centerview Partners also served as a financial advisor, and Walder Wyss acted as legal advisor. EY provided advisory on financial, tax, compliance, and legal vendor due diligence services, and BCG supported commercial vendor due diligence.
KEY QUOTES:
“We are excited to partner with Swixx BioPharma, a company that shares our commitment to improving patient outcomes and advancing healthcare. Our investment underscores confidence in Swixx’s leadership and its ability to deliver sustainable business growth across diverse markets.”
Aaron Davenport, Managing Director at SK Capital
“This partnership marks a pivotal moment for Swixx, bringing both additional capital and expertise to drive our growth. We remain committed to expanding our role as the trusted partner for leading global biopharmaceutical companies, delivering sustainable outsourcing solutions in complex and emerging markets—and ultimately improving access and outcomes for patients.”
Jean-Michel Lespinasse, Swixx’s CEO
